Delivery Order SPE2DB24D2106-SPE2DB24FATWV
- Not listed
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $22,461.51, is for the delivery of Cosentyx 300mg dose prefilled syringes. The contract does not have a set-aside designation and is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables...
- The Defense Logistics Agency awarded a $16.8K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pen injections. The order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed-price delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million and valid through November...
- The Defense Logistics Agency awarded a delivery order valued at $13,735.58 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2-pen/mL formulation on August 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a pharmaceutical supply requirement with performance taking place in Conshohocken, Pennsylvania. The award was made without set-aside designation to DMS Pharmaceutical Group, a woman-owned small business...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $34,859.08 contract is for the supply of Cosentyx, a prescription medication, to support the medical needs of military healthcare facilities. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC allows the DLA to issue delivery orders for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,382.36, is for the delivery of 4,568,020,330 units of the prescription drug Cosentyx (300 mg/2 mL) by April 22, 2025. The contract type is firm fixed price. This award is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at...
- On August 20, 2025, the Defense Logistics Agency awarded a delivery order valued at $10,461.10 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300 mg pen 2 mL injections. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract does not utilize a set-aside designation, and the pharmaceutical products will be...
- This federal contract award, valued at $19,934.38, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is a firm fixed-price delivery order for the supply of Cosentyx (secukinumab) 300 mg doses. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $31,640.70 contract is for the supply of Cosentyx 300 mg pen injectors. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide range of pharmaceutical products to support the medical supply...
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,911.80 contract is for the delivery of Cosentyx Unoready 300 mg pens to the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of October 23, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
- The Defense Logistics Agency awarded a delivery order valued at $4,200.08 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300 mg pen 2 ml on August 25, 2025, with completion expected by August 26, 2025. This firm fixed-price delivery order represents a specific pharmaceutical requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at $499.999 billion and extending through November 2026. The award carries no...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB24FATWVDelivery Order
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of Cosentyx (secukinumab) 300 mg dose autoinjectors, a specialized biologic medication used to treat certain medical conditions. The contract is a firm fixed-price delivery order with a ceiling value of $9,162.16 and a period of performance through March 13, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at $499,999,999 and valid through November 2026. The IDC allows the DLA to issue delivery orders for a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 3/12/24 |